Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Richard J. Bold

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1181-1573; OpenAlex author ID A5066602644. Sources: OpenAlex.

Their work

Papers
22 (first author 2, last author 6)
Trials
0
Grants
0
Labs led
2
Collaborators
52
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 1 paper · 2014: 2 papers · 2015: 2 papers · 2016: none · 2017: none · 2018: 1 paper · 2019: 2 papers · 2020: none · 2021: 1 paper · 2022: 2 papers · 2023: none · 2024: 3 papers · 2025: 1 paper · 2026: 6 papers

Papers 22

  1. Adjuvant Chemotherapy Is Not Associated With Improved Overall Survival in Patients With Pancreatic Ductal Adenocarcinoma With Persistent Lymphovascular Invasio… Co-author DOI 10.1002/jso.70414↗
  2. Do Postoperative Complications Impact Adjuvant Chemotherapy in Patients Undergoing Left-Side Pancreatectomy for Pancreatic Cancer? Co-author DOI 10.1245/s10434-026-19739-2↗
  3. ASO Visual Abstract: Do Postoperative Complications Impact Adjuvant Chemotherapy for Patients Undergoing Left-Side Pancreatectomy for Pancreatic Cancer? Co-author DOI 10.1245/s10434-026-19795-8↗
  4. Correction: Do Postoperative Complications Impact Adjuvant Chemotherapy in Patients Undergoing Left-Side Pancreatectomy for Pancreatic Cancer? Co-author DOI 10.1245/s10434-026-20347-3↗
  5. Editorial Comment: What's in an Accreditation? Cancer Center Designation and Outcomes in Pancreatic Cancer. First author DOI 10.1245/s10434-026-20625-0↗
  6. Redefining Upfront Resectable Pancreatic Ductal Adenocarcinoma: Should Vein Abutment Matter? Co-author DOI 10.6004/jnccn.2025.7097↗
  7. Genetically proxied risk and protective factors for pancreatic cancer: a systematic review and meta-analysis of Mendelian randomization studies. Co-author DOI 10.21037/jgo-2025-305↗
  8. Characterization of natural killer and cytotoxic T-cell immune infiltrates in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jso.27581↗
  9. The impact of the California state lockdown during the COVID-19 pandemic on management of patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jso.27695↗
  10. Whole-genome bisulfite sequencing identifies stage- and subtype-specific DNA methylation signatures in pancreatic cancer. Co-author DOI 10.1016/j.isci.2024.109414↗
  11. Evaluation of Adherence to Venous Thromboembolism Prophylaxis Guidelines Among US Adults After Pancreatic Cancer Surgery. Co-author DOI 10.1001/jamasurg.2022.2590↗
  12. The Impact of Preexisting Psychiatric Disorders on Outcomes After Pancreatic Cancer Surgery. Last author DOI 10.1097/mpa.0000000000002200↗
  13. Is Improved Survival in Early-Stage Pancreatic Cancer Worth the Extra Cost at High-Volume Centers? Co-author DOI 10.1016/j.jamcollsurg.2021.02.014↗
  14. Defining Value for Pancreatic Surgery in Early-Stage Pancreatic Cancer. Last author DOI 10.1001/jamasurg.2019.3019↗
  15. Bioengineered miRNA-1291 prodrug therapy in pancreatic cancer cells and patient-derived xenograft mouse models. Co-author DOI 10.1016/j.canlet.2018.10.038↗
  16. Currently available first-line drug therapies for treating pancreatic cancer. First author DOI 10.1080/14656566.2018.1509954↗
  17. Preoperative CA 19-9 kinetics as a prognostic variable in radiographically resectable pancreatic adenocarcinoma. Last author DOI 10.1002/jso.23812↗
  18. Long-Term Progression-Free Survival in a Patient with Locally Advanced, Unresectable Pancreatic Adenocarcinoma. Co-author DOI 10.7759/cureus.406↗
  19. Pegylated arginine deiminase synergistically increases the cytotoxicity of gemcitabine in human pancreatic cancer. Last author DOI 10.1186/preaccept-8245834981349245↗
  20. Role of autophagy in apoptotic regulation by Akt in pancreatic cancer. Last author PMID 24510992↗
  21. Re: CA 19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and preoperative therapy. Co-author DOI 10.1245/s10434-012-2820-6↗
  22. Factors affecting treatment delivery and outcomes of patients with early-stage pancreatic adenocarcinoma. Last author DOI 10.1097/mpa.0b013e318205eab0↗

Closest collaborators

The 25 strongest of 52 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zhi Ven Fong · 6 shared papers, 2026 · strength 1.83
  2. Nabil Wasif · 5 shared papers, 2026 · strength 1.33
  3. Chee‐Chee Stucky · 5 shared papers, 2026 · strength 1.33
  4. Stephanie Yu · 4 shared papers, 2026 · strength 1.29
  5. Dillon C. Cheung · 3 shared papers, 2026 · strength 0.79
  6. Lauren M. Perry · 4 shared papers, 2021–2024 · strength 0.74
  7. Robert J. Canter · 5 shared papers, 2011–2024 · strength 0.62
  8. Sarah B. Bateni · 3 shared papers, 2019–2022 · strength 0.49
  9. Jeffrey S. Hoch · 2 shared papers, 2019–2021 · strength 0.32
  10. Mitesh J. Borad · 1 shared paper, 2026 · strength 0.30
  11. Yu-Hui H. Chang · 1 shared paper, 2026 · strength 0.30
  12. Valerie L. Armstrong · 1 shared paper, 2026 · strength 0.30
  13. Tanios Bekaii‐Saab · 1 shared paper, 2026 · strength 0.30
  14. Atsushi Yamaguchi · 1 shared paper, 2025 · strength 0.27
  15. Li Zhang · 1 shared paper, 2025 · strength 0.27
  16. Fada Luo · 1 shared paper, 2025 · strength 0.27
  17. Somashekar Gopala Krishna · 1 shared paper, 2025 · strength 0.27
  18. Po Hong Tan · 1 shared paper, 2026 · strength 0.24
  19. John Andrew Stauffer · 1 shared paper, 2026 · strength 0.24
  20. Susanne Gray Warner · 1 shared paper, 2026 · strength 0.24
  21. Michael L. Kendrick · 1 shared paper, 2026 · strength 0.24
  22. Cornelius A. Thiels · 1 shared paper, 2026 · strength 0.24
  23. Mark Joseph Truty · 1 shared paper, 2026 · strength 0.24
  24. Katherine E. Poruk · 1 shared paper, 2026 · strength 0.24
  25. Sean James Judge · 1 shared paper, 2024 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.